Ketesse

# Ketesse ## Overview - **Classification**: Nonsteroidal Anti-inflammatory Drug (NSAID), propionic acid derivative - **Mechanism**: Potent reversible inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. ## Primary Indications 1. **Mild to Moderate Pain**: Symptomatic treatment of acute pain (e.g., musculoskeletal pain, dysmenorrhea, dental pain). 2. **Acute Moderate to Severe Pain**: Postoperative pain (injectable formulation). ## Adult Dosing ### Standard Dosing **Mild to Moderate Pain (Oral)** - **Dose**: **12.5 mg** - **Frequency**: Every 4-6 hours (q4-6h) - **Route**: Oral (tablet, sachet) - **Maximum Dose**: **75 mg/day** - **Special Considerations**: Take with food or milk if GI upset occurs, though absorption may be delayed. For faster onset, take 30 min before food. **OR** - **Dose**: **25 mg** - **Frequency**: Every 8 hours (q8h) - **Route**: Oral (tablet, sachet) - **Maximum Dose**: **75 mg/day** **Acute Moderate to Severe Pain (Parenteral)** - **Dose**: **50 mg** - **Frequency**: Every 8-12 hours (q8-12h) - **Route**: Intramuscular (IM) or Intravenous (IV) bolus/infusion - **Maximum Dose**: **150 mg/day** - **Duration**: Short-term, usually not exceeding 48-72 hours. ### Dose Adjustments - **Renal Impairment**: - **CrCl 30-59 mL/min**: Reduce total daily dose to **50 mg/day** (e.g., 25 mg q12h or 12.5 mg q6h oral). - **CrCl <30 mL/min**: **Contraindicated**. - **Hepatic Impairment**: - **Mild-to-moderate (Child-Pugh A or B)**: Reduce total daily dose to **50 mg/day** (e.g., 25 mg q12h oral). - **Severe (Child-Pugh C)**: **Contraindicated**. - **Elderly Patients**: Start at lower dose; total daily dose **50 mg/day** (e.g., 25 mg q12h oral). Monitor renal function closely. ## Pediatric Dosing Dexketoprofen is **generally not recommended** for use in pediatric populations (children and adolescents <18 years of age) due to limited safety and efficacy data. ### Neonates (0-28 days) - **Dose**: **Not recommended**. - **Special Notes**: Safety and efficacy are **not established**. Avoid use. ### Infants (1-12 months) - **Dose**: **Not recommended**. - **Special Notes**: Safety and efficacy are **not established**. Avoid use. ### Children (1-12 years) - **Dose**: **Not recommended**. - **Special Notes**: Safety and efficacy are **not established**. Avoid use. ### Adolescents (13-18 years) - **Dose**: **Not generally recommended**. - **Special Notes**: In specific cases and with careful consideration, some clinicians *may* cautiously consider adult doses for short-term pain relief if other NSAIDs are unsuitable. Always weigh risks vs. benefits. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to dexketoprofen or other NSAIDs (e.g., asthma, urticaria, angioedema). - **Absolute**: Active peptic ulcer, GI bleeding, or history of recurrent GI bleeding/perforation. - **Absolute**: Severe heart failure, moderate-to-severe renal impairment (CrCl <30 mL/min), severe hepatic impairment. - **Absolute**: Bleeding disorders, Crohn's disease, ulcerative colitis. - **Absolute**: Third trimester of pregnancy, lactation. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, abdominal pain, dyspepsia. - **Common (1-10%)**: Diarrhea, headache, dizziness, somnolence, insomnia, fatigue. - **Common (1-10%)**: Injection site reactions (for parenteral form). - **Serious but Rare**: Gastrointestinal ulceration/bleeding/perforation, acute kidney injury. - **Serious but Rare**: Severe allergic reactions (anaphylaxis, angioedema), Stevens-Johnson Syndrome. - **Serious but Rare**: Thrombotic cardiovascular events (MI, stroke), hypertension, heart failure exacerbation. ### Key Drug Interactions - **Anticoagulants (e.g., warfarin, heparin)**: Increased risk of serious bleeding. - **Other NSAIDs/Corticosteroids**: Increased GI adverse effects, bleeding risk. Avoid concomitant use. - **Lithium**: Increased plasma lithium levels, leading to toxicity. Monitor lithium levels. - **Methotrexate (high dose >15 mg/week)**: Significantly increased methotrexate toxicity. Avoid concomitant use. - **Diuretics, ACE inhibitors, ARBs**: Reduced antihypertensive effect, increased risk of renal impairment. Monitor renal function and blood pressure. - **SSRIs**: Increased risk of gastrointestinal bleeding. - **Cyclosporine/Tacrolimus**: Increased risk of nephrotoxicity. ## Monitoring & Follow-up - **Before Treatment**: Assess renal function (CrCl), liver function (if high risk). - **During Treatment**: Monitor for signs of GI bleeding (e.g., dark stools, coffee-ground emesis). - **During Treatment**: Monitor renal function in high-risk patients (elderly, heart failure, diuretic use). - **Clinical Signs**: Watch for unusual bleeding/bruising, swelling, chest pain, shortness of breath, persistent abdominal pain, changes in urination. ## Clinical Pearls - 💡 **Tip 1**: For fastest pain relief, take **30 minutes before food**. If GI upset occurs, take with food/milk. - 💡 **Tip 2**: Use the **lowest effective dose** for the **shortest duration** to minimize GI, renal, and cardiovascular risks. - 💡 **Tip 3**: Ensure adequate hydration, especially in elderly or patients on diuretics, to reduce renal adverse effects. - 💡 **Tip 4**: Counsel patients on signs of GI bleeding and serious allergic reactions, and to seek immediate medical attention if they occur. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.